BR112018008136A2 - peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo - Google Patents
peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivoInfo
- Publication number
- BR112018008136A2 BR112018008136A2 BR112018008136A BR112018008136A BR112018008136A2 BR 112018008136 A2 BR112018008136 A2 BR 112018008136A2 BR 112018008136 A BR112018008136 A BR 112018008136A BR 112018008136 A BR112018008136 A BR 112018008136A BR 112018008136 A2 BR112018008136 A2 BR 112018008136A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- peptide
- absent
- side chain
- disorder
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518700.8A GB2543550A (en) | 2015-10-21 | 2015-10-21 | Peptides |
| PCT/GB2016/053282 WO2017068353A1 (en) | 2015-10-21 | 2016-10-20 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018008136A2 true BR112018008136A2 (pt) | 2018-11-06 |
Family
ID=55131441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018008136A BR112018008136A2 (pt) | 2015-10-21 | 2016-10-20 | peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10494412B2 (OSRAM) |
| EP (2) | EP3364992B1 (OSRAM) |
| JP (1) | JP2018533570A (OSRAM) |
| KR (1) | KR20180080217A (OSRAM) |
| CN (1) | CN108430491A (OSRAM) |
| AU (1) | AU2016341494A1 (OSRAM) |
| BR (1) | BR112018008136A2 (OSRAM) |
| CA (1) | CA3002739A1 (OSRAM) |
| EA (1) | EA201890900A1 (OSRAM) |
| ES (1) | ES2775740T3 (OSRAM) |
| GB (1) | GB2543550A (OSRAM) |
| MX (1) | MX2018004930A (OSRAM) |
| WO (1) | WO2017068353A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121287874B (zh) * | 2025-12-12 | 2026-03-17 | 广州飞来爱生命科技有限公司 | 一种治疗前列腺疾病的间充质干细胞组合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE69534077T2 (de) * | 1994-01-14 | 2005-08-11 | Rath, Matthias, Dr.med. | Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden |
| US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| AR034118A1 (es) | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| PA8535501A1 (es) | 2001-01-05 | 2003-07-28 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| GB0229151D0 (en) * | 2002-12-13 | 2003-01-15 | St Georges Entpr Ltd | Product and method |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7259266B2 (en) | 2003-03-31 | 2007-08-21 | Pharmacia Corporation | Benzopyran compounds useful for treating inflammatory conditions |
| US20050148627A1 (en) | 2003-03-31 | 2005-07-07 | Jeffery Carter | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| EP1909811B1 (en) * | 2005-06-29 | 2012-02-01 | St. George's Enterprises Limited | Hox peptides as pbx modulators for the treatment of cancer |
| US7928186B2 (en) * | 2006-08-02 | 2011-04-19 | Phoenix Pharmaceuticals, Inc. | Cell permeable bioactive peptide conjugates |
| KR101863136B1 (ko) * | 2008-01-24 | 2018-05-31 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법 |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2015
- 2015-10-21 GB GB1518700.8A patent/GB2543550A/en not_active Withdrawn
-
2016
- 2016-10-20 JP JP2018520389A patent/JP2018533570A/ja active Pending
- 2016-10-20 AU AU2016341494A patent/AU2016341494A1/en not_active Abandoned
- 2016-10-20 KR KR1020187012506A patent/KR20180080217A/ko not_active Withdrawn
- 2016-10-20 US US15/770,023 patent/US10494412B2/en active Active
- 2016-10-20 EP EP16801003.1A patent/EP3364992B1/en active Active
- 2016-10-20 EA EA201890900A patent/EA201890900A1/ru unknown
- 2016-10-20 CN CN201680074733.7A patent/CN108430491A/zh active Pending
- 2016-10-20 ES ES16801003T patent/ES2775740T3/es active Active
- 2016-10-20 MX MX2018004930A patent/MX2018004930A/es unknown
- 2016-10-20 CA CA3002739A patent/CA3002739A1/en not_active Abandoned
- 2016-10-20 BR BR112018008136A patent/BR112018008136A2/pt not_active Application Discontinuation
- 2016-10-20 EP EP19200535.3A patent/EP3610883A1/en not_active Withdrawn
- 2016-10-20 WO PCT/GB2016/053282 patent/WO2017068353A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3364992A1 (en) | 2018-08-29 |
| ES2775740T3 (es) | 2020-07-28 |
| CA3002739A1 (en) | 2017-04-27 |
| GB2543550A (en) | 2017-04-26 |
| CN108430491A (zh) | 2018-08-21 |
| EP3364992B1 (en) | 2019-12-04 |
| KR20180080217A (ko) | 2018-07-11 |
| EA201890900A1 (ru) | 2018-10-31 |
| ES2775740T8 (es) | 2020-08-06 |
| US10494412B2 (en) | 2019-12-03 |
| JP2018533570A (ja) | 2018-11-15 |
| GB201518700D0 (en) | 2015-12-02 |
| MX2018004930A (es) | 2018-11-09 |
| WO2017068353A1 (en) | 2017-04-27 |
| EP3610883A1 (en) | 2020-02-19 |
| AU2016341494A1 (en) | 2018-05-24 |
| US20180282384A1 (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351865B (es) | Composiciones de raav-guanilato ciclasa y metodos para el tratamiento de la amaurosis congenita de leber 1 (lca1). | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| BR112015018255A2 (pt) | Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia | |
| BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112014033102A2 (pt) | produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
| BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
| BR112018072034A2 (pt) | compostos mic-1 e usos dos mesmos | |
| BR112015014367A2 (pt) | formulações inibidoras de lfa-1 | |
| BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| BR112015028414A2 (pt) | composição farmacêutica de micela de polímero | |
| MX2021008941A (es) | Moduladores gpr35. | |
| BR112017008702A2 (pt) | ?mutante de endoxilanase, dna, vetor, célula, método de produção de mutantes de endoxilanase, composição enzimática e método de produção de solução de açúcar? | |
| CO2018011586A2 (es) | Inhibidor de esterasa c1 conjugado y sus usos | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| BR112017019431A2 (pt) | material de implante de compósito |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |